Fintel reports that on March 17, 2025, Laidlaw & Co. initiated coverage of Nuvectis Pharma (NasdaqCM:NVCT) with a Buy recommendation.
Analyst Price Forecast Suggests 115.14% Upside
As of March 4, 2025, the average one-year price target for Nuvectis Pharma is $19.04/share. The forecasts range from a low of $11.11 to a high of $26.25. The average price target represents an increase of 115.14% from its latest reported closing price of $8.85 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Nuvectis Pharma is 24MM. The projected annual non-GAAP EPS is -1.55.
What is the Fund Sentiment?
There are 45 funds or institutions reporting positions in Nuvectis Pharma. This is an decrease of 45 owner(s) or 50.00% in the last quarter. Average portfolio weight of all funds dedicated to NVCT is 0.00%, an increase of 19.74%. Total shares owned by institutions decreased in the last three months by 2.04% to 1,345K shares. 
The put/call ratio of NVCT is 0.97, indicating a bullish outlook.
What are Other Shareholders Doing?
Baldwin Brothers holds 356K shares representing 1.52% ownership of the company. In its prior filing, the firm reported owning 174K shares , representing an increase of 51.08%. The firm increased its portfolio allocation in NVCT by 16.27% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 231K shares representing 0.99% ownership of the company. No change in the last quarter.
Marshall Wace, Llp holds 125K shares representing 0.53% ownership of the company. In its prior filing, the firm reported owning 43K shares , representing an increase of 65.63%. The firm increased its portfolio allocation in NVCT by 14.49% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 82K shares representing 0.35% ownership of the company. In its prior filing, the firm reported owning 57K shares , representing an increase of 30.24%. The firm increased its portfolio allocation in NVCT by 18.91% over the last quarter.
Geode Capital Management holds 79K shares representing 0.34% ownership of the company. In its prior filing, the firm reported owning 80K shares , representing a decrease of 0.60%. The firm decreased its portfolio allocation in NVCT by 56.93% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
